Press Releases
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Read the Latest
Calidi Biotherapeutics and City of Hope announce first patient dosed in a Phase 1 clinical trial evaluating neural stem cells engineered to carry an oncolytic virus, CLD-101, in recurrent high-grade glioma patients
FOR IMMEDIATE RELEASE July 18, 2023 LOS ANGELES & SAN DIEGO–(BUSINESS WIRE)– City of…
Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer
Financing led by Jackson Investment Group (JIG) with participation from Calidi Cure, LLC, a consortium…
Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies
-Total gross proceeds from the transaction, before payment of transaction expenses, expected to be up…
Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs
Calidi was awarded $3.1 million to support the development of Supernova-1 (SNV1) program through IND…
Calidi Biotherapeutics to Present at the 7th Annual Oncolytic Virotherapy Summit
LA JOLLA, Calif. (December 6, 2022) — Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company…
Calidi Biotherapeutics Presents Promising Pre-Clinical Data from SuperNova-1 (SNV1), a Novel Oncolytic-Cell Based Platform, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022)
LA JOLLA, CALIF (November 7, 2022) — Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company…